Skip to content

Dr. De Geronimo Daniele

FondazioneBietti_De Geronimo Daniele
Research line: Medical and surgical retina
Research unit: UR Medical Retina
Simple Operating Unit: Simple Operating Unit Medical Retina, low vision and visual rehabilitation 
Main specializations: DIABETIC RETINOPATHY, AGE-RELATED MACULAR DEGENERATION (AMD), REFRACTIVE ERRORS, RETINAL VEIN OCCLUSION

Medical activity: Works at IRCCS G.B. Bietti in the offices of Via Livenza, 3 and Via di Santo Stefano Rotondo 6, Rome

Scientific publication : PubMed

E-mail: daniele.degeronimo@fondazionebietti.it

• 2012 – Diploma of Specialist in Ophthalmology at the “Sapienza” University of Rome with full marks and

honors.

• 2011-2012 – Uveitis and Medical Retina Fellowship at Moorfields Eye Hospital, London, UK.

• 2007 – Degree in Medicine and Surgery at the “Sapienza” University of Rome with full marks and honors.

Since 2013 – Researcher in the Medical Retina Unit IRCCS – Fondazione Bietti

• Since 2015 – Clinical and research activity for IRCCS Fondazione Bietti at Presidio Britannico in Rome

• Since 2013 – Researcher in the Medical Retina Unit IRCCS – Fondazione Bietti

  • Member of “Società Italiana di Scienze Oftalmologiche” (SISO)
  • Member of “Società Italiana Uveiti e Malattie Infiammatorie Oculari” (SIUMIO)
  • Member of “Società Italiana della Retina” (SIR)
  • Member of “Association for Research in Vision and Ophthalmology “(ARVO)

Sub-investigator in the following clinical trials:

 

  • A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA). Novartis. Sub-Investigator.
  • A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular agerelated macular degeneration (TREND). Novartis. Sub-Investigator.
  • A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration ( Fovista-OPH1002 ). Ophthotec. Study Coordinator.
  • A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration. (CHROMA)
  • A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (Fovista-OPH1004) 
  • Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA)
  • Retinal and cognitive dysfunction in Type 2 Diabetes: unraveling the common pathways and identification of patients at risk of dementia (RECOGNISED)
  • Characterization of retinal disease progression in eyes with NPDR in Diabetes Type 2 using non-trattive invasive procedures (CHART)
  • Acta Ophthalmologica
  • Acta Diabetologica
  • European Journal Of Ophthalmology
  • Ophthalmologica
  • Scientific Reports
  • Diabetes Therapy
  • BMC Ophthalmology
  • American Journal of Case Reports
  • Author of 22 publications on international ophthalmological journals.
  • Author of 4 chapters of book.
Skip to content